Microarray Analysis of Scalp Biopsies After Minoxidil Treatment

Exclusion Criteria

• •1. Evidence of concomitant skin diseases of the scalp including but not limited to dandruff, seborrheic dermatitis, psoriasis, lichenoid eruption, tinea capitis or other scalp infections or infestations.
• •2. Has a history of recurring dandruff symptoms or seborrheic dermatitis, evidence of excoriations, or other history that might indicate an inability to use the products supplied for the duration of the study.
• •3. Has consistently used any medicated shampoos or anti-dandruff shampoo treatment products over the past year or at all during the two months prior to the Baseline visit.
• •4. Has a history of alopecia areata, totalis, universalis or any other hair loss disorder except male pattern baldness.
• •5. Evidence of significant scalp scarring.
• •6. Has skin cancer or actinic keratoses currently within the balding area.
• •7. Has a history of skin cancer on the scalp.
• •8. Has undergone a hair transplant or scalp reduction surgery.
• •9. Has exhibited hypersensitivity, rash or other abnormal skin reactions, symptoms or lesions to topically applied hair care products in the past year.
• •10. Has been diagnosed with hypothyroidism or hyperthyroidism within the past year.
• •11. Has taken or applied any of the following medications known to induce hypotrichosis (abnormal hair loss), and/or hypertrichosis (abnormal hair growth).
• •Medications taken or used in the past 6 months
• •* Finasteride -hair growth product (PropeciaÒ or ProscarÒ)
• •* Topical or systemic hair growth products (commercial or investigative) e.g. minoxidil (RogaineÒ), NioxinÒ, dutasteride
• •* Chemotherapeutic agents
• •* Systemic Retinoids (e.g. acitretin, etretinate, isotretinoin, Vitamin A \> 5,000 IU (per day)
• •* Immunosuppressives (e.g. tacrolimus, cyclosporine A)
• •* Antimetabolic agents. (e.g. FludaraÒ, LeustatinÒ
• •* Antimitotic agents
• •* Anti-androgens (e.g. flutamide, spironolactone, cyproterone acetate)
• •* Androgens (e.g. testosterone, methyl testosterone, danazol)
• •* DHEA, androstenedione
• •* Ketaconazole -systemic (antifungal)
• •* Ginseng (herb)
• •* Saw Palmetto
• •* Diazoxide (hyperglycemic, antihypertensive agent)
• •* Anticoagulants (e.g. dicumarol, heparin, warfarin)
• •* Interferon
• •* Beta blockers (e.g. AcebutololÒ,, AtenololÒ, propranolol, TimololÒ, MetoprololÒ)
• •* Antiepileptic and anticonvulsants (e.g. valproic acid, carbamazepine, diphenylhydantoin)
• •* Antithyroid drugs (e.g. carbimazole, methimazole, methylthiouracil, propylthiouracil)
• •* Topical corticosteroids on scalp or applied to more than 25% of the body surface area
• •* Systemic corticosteroids
• •* Topical ketaconazole shampoo or cream
• •12. Has a significant medical condition including, but not limited to:
• •Hypertension (acceptable if controlled by other than a beta blocker); angina, myocardial infarction; history of fainting or dizziness; history of kidney or urinary disorders; diabetes; hemophilia or any condition determined by the Investigator as significant and therefore considered a cause for exclusion
• •13. Has recently been on, or is currently on a medically managed weight reduction program.
• •14. Has had a significant febrile illness (high fever lasting several days) within 8 weeks of the Baseline visit.
• •15. Has participated in an investigational drug study within 4 weeks of the Baseline visit.